Trials Evaluating Ziritaxestat for Idiopathic Pulmonary Fibrosis Discontinued
Ziritaxestat is an investigational autotaxin inhibitor.
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis May Be Associated With Gastroesophageal Reflux Disease
Patients with idiopathic pulmonary fibrosis (IPF) have nearly double the risk of having gastroesophageal reflux disease (GERD) compared with the general population.
Diagnosing Hypersensitivity Pneumonitis: A New Clinical Practice Guideline
A multidisciplinary committee of international experts have released a new clinical practice guideline on the diagnosis of adult hypersensitivity pneumonitis, an immune-mediated inflammatory lung and small airway disease.
Nintedanib’s Adverse Event Profile in SSc-ILD Consistent With Safety, Tolerability in Idiopathic Pulmonary Fibrosis
Researchers characterized the safety and tolerability of nintedanib and the dose adjustments for adverse events in patients with systemic sclerosis-associated interstitial lung disease.
Pulmonary Fibrosis Awareness Month: Spotlight on the PFF Care Center Network
As a central goal of PF Awareness Month and their ongoing work, the Pulmonary Fibrosis Foundation aims to improve diagnostic delays and misdiagnoses in this patient population.
Bronchoalveolar Lavage Appears Safe, Well Tolerated in Idiopathic Pulmonary Fibrosis
In patients with COPD, lung methylation profiles differ according to the severity of airflow limitation and some epigenetic changes translate into specific gene expression changes in the lung.
Comparing Mortality Risks Between Idiopathic Pulmonary Fibrosis Treatments
In patients with idiopathic pulmonary fibrosis, treatment with pirfenidone was associated with a lower risk of mortality and acute respiratory-related hospitalizations than treatment with nintedanib.
Effect of COVID-19 on Pulmonary Fibrosis Clinical Trials: Expert Interview
Individuals with pulmonary fibrosis could develop more serious complications if infected with COVID-19, and those awaiting organ transplantation and other surgical interventions may face delays because of the pandemic.
Pulmonary Hypertension With ILD: Diagnostic and Treatment Challenges
Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
Circulating mtDNA Is a Promising Biomarker in Idiopathic Pulmonary Fibrosis
An increase in circulating serum mitochondrial DNA is associated with worse survival in patients with newly diagnosed idiopathic pulmonary fibrosis.
-
Loading...
-
Loading...
Next post in ATS 2020
